{{Rsnum
|rsid=11545077
|Gene=GGH
|Chromosome=8
|position=63038678
|Orientation=minus
|GMAF=0.2029
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=GGH
}}{{PharmGKB
|RSID=rs11545077
|Name_s=GGH: Exon 1, 91C>T, p.Ala31Thr
|Gene_s=GGH
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19841321
|Annotation=Risk or phenotype-associated allele: T. Phenotype: The T allele was marginally associated with increased overall survival (CC vs. TC: 6.5, 14.1 months) given combined pemetrexed/bevacizumab treatment. Study size: from a study using 48 patients with metastatic or stage IIIB nonsquamous non-small-cell lung cancer patients. Significance metric(s): p = 0.06 Type of association: CO, GN
|Drugs=bevacizumab; pemetrexed
|Drug Classes=
|Diseases=Carcinoma, Non-Small-Cell Lung
|Curation Level=Curated
|PharmGKB Accession ID=PA165109564
}}

{{ population diversity
| geno1 = (C;C)
| geno2 = (C;T)
| geno3 = (T;T)
| CEU | 51.3 | 40.7 | 8.0
| CHB | 60.5 | 34.9 | 4.7
| JPT | 50.6 | 43.5 | 5.9
| YRI | 82.3 | 16.8 | 0.9
}}{{GET Evidence
|gene=GGH
|aa_change=Ala31Thr
|aa_change_short=A31T
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11545077
|overall_frequency_n=2254
|overall_frequency_d=10738
|overall_frequency=0.209909
|n_genomes=15
|n_genomes_annotated=0
|n_haplomes=17
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|nblosum100=1
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}